Ultragenyx Pharmaceutical
RARE
300 hedge funds and large institutions have $3.25B invested in Ultragenyx Pharmaceutical in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 128 increasing their positions, 104 reducing their positions, and 44 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
32% more capital inflows, than outflows
Capital inflows: $396M | Capital outflows: $301M
23% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 104
2.35% more ownership
Funds ownership: 94.7% → 97.05% (+2.4%)
4% more call options, than puts
Call options by funds: $43.9M | Put options by funds: $42.2M
4% less funds holding
Funds holding: 313 → 300 (-13)
30% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$40.2M |
| 2 |
Suvretta Capital Management
New York
|
+$36.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.4M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
+$29M |
| 5 |
Polar Capital Holdings
London,
United Kingdom
|
+$27.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
-$41.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$29.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$22M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$20.2M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$15.8M |
RARE Hedge Fund Activity: Q1 2025 in Review
300 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2025, worth a combined $3.25B — down 12% from $3.68B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of RARE and 31 opened new positions — a net loss of 13 holders — while 104 trimmed existing stakes and 128 added.
The largest buyer was Adage Capital Partners, adding an estimated $40.2M. The largest seller was Vestal Point Capital, cutting an estimated $41.6M.
- 300 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2025, down from 313 in Q4 2024.
- Funds reported $3.25B of Ultragenyx Pharmaceutical stock for Q1 2025, down 12% quarter-over-quarter.
- 31 funds opened new Ultragenyx Pharmaceutical positions in Q1 2025 and 44 closed out, a net change of -13 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2025 was Adage Capital Partners, an estimated $40.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2025 was Vestal Point Capital, an estimated $41.6M sold.
Based on aggregated 13F filings for Q1 2025.